Literature DB >> 15176076

Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles.

Toshihiro Wajima1, Yoshitaka Yano, Kazuya Fukumura, Takayoshi Oguma.   

Abstract

The aim of the present study was to develop a method for predicting the concentration-time profile in humans based on pharmacokinetic data for animals. The method is based on the assumptions that concentration-time profiles of a drug are similar among species and "normalized curves" from a variety of animal species including humans can be superimposed. Normalized curves are obtained by normalizing the time axis with the MRT (mean residence time) and the concentration axis with dose/Vdss, where Vdss is the volume of distribution at steady state. The concentration-time profile in humans after intravenous injection can be simulated using the normalized curve for an animal and the predicted values of clearance (CL) and Vdss for humans. Although the general idea of our method is similar to the Dedrick plots, ours is superior in that it enables the use of predicted CL and Vdss values from any method. Our method was applied to some drugs using actual published data sets, and the assumption of the similarity of concentration-time profiles among species was found to be acceptable for these drugs. The results for the prediction of concentration-time profiles for humans were also acceptable. This method can be applied to any drug on the assumption that normalized curves from a variety of species can be superimposed. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1890-1900, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15176076     DOI: 10.1002/jps.20099

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  18 in total

Review 1.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

2.  Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data.

Authors:  Tycho Heimbach; Suresh B Lakshminarayana; Wenyu Hu; Handan He
Journal:  AAPS J       Date:  2009-08-26       Impact factor: 4.009

Review 3.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

4.  UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Authors:  Christel Brunschwig; Nina Lawrence; Dale Taylor; Efrem Abay; Mathew Njoroge; Gregory S Basarab; Claire Le Manach; Tanya Paquet; Diego Gonzàlez Cabrera; Aloysius T Nchinda; Carmen de Kock; Lubbe Wiesner; Paolo Denti; David Waterson; Benjamin Blasco; Didier Leroy; Michael J Witty; Cristina Donini; James Duffy; Sergio Wittlin; Karen L White; Susan A Charman; Maria Belén Jiménez-Díaz; Iñigo Angulo-Barturen; Esperanza Herreros; Francisco Javier Gamo; Rosemary Rochford; Dalu Mancama; Theresa L Coetzer; Mariëtte E van der Watt; Janette Reader; Lyn-Marie Birkholtz; Kennan C Marsh; Suresh M Solapure; John E Burke; Jacob A McPhail; Manu Vanaerschot; David A Fidock; Paul V Fish; Peter Siegl; Dennis A Smith; Grennady Wirjanata; Rintis Noviyanti; Ric N Price; Jutta Marfurt; Kigbafori D Silue; Leslie J Street; Kelly Chibale
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

5.  Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery.

Authors:  N Gobeau; R Stringer; S De Buck; T Tuntland; B Faller
Journal:  Pharm Res       Date:  2016-06-08       Impact factor: 4.200

6.  Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery.

Authors:  An Van den Bergh; Vikash Sinha; Ron Gilissen; Roel Straetemans; Koen Wuyts; Denise Morrison; Luc Bijnens; Claire Mackie
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

7.  Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2013-04-25       Impact factor: 3.534

8.  Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.

Authors:  Matthew P Kosloski; Dipak S Pisal; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2014-01-02       Impact factor: 1.627

Review 9.  Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.

Authors:  Nigel J Waters
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

10.  Projection of exposure and efficacious dose prior to first-in-human studies: how successful have we been?

Authors:  Christine Huang; Ming Zheng; Zheng Yang; A David Rodrigues; Punit Marathe
Journal:  Pharm Res       Date:  2007-09-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.